The earnings call reflects strong progress in clinical trials and financial stability with accelerated enrollment and positive interim data, balanced by the forthcoming retirement of the CMO and some reported adverse events.

Company Guidance -

Q3 2025

During Intellia Therapeutics' second quarter 2025 financial results call, the company detailed several key metrics and projections. They anticipate launching Lonvo-z for HAE by the first half of 2027, supported by a financial runway through multiple major milestones. Clinical programs are advancing rapidly, with Phase III studies across Lonvo-z and nex-z enrolling faster than expected. The company plans to increase the enrollment for the Phase III study of nex-z in ATTR cardiomyopathy to approximately 1,200 patients, which is expected to provide a robust data set. They are targeting at least 650 patients cumulatively by year-end, up from an earlier guidance of more than 550. Financially, Intellia reported a cash position of $630.5 million as of June 30, 2025, and expects a year-over-year decline in GAAP operating expenses, guiding to an approximately 10% decline. Revenue for the quarter was $14.2 million, up from $6.9 million in the prior year, driven by collaborations, while R&D expenses decreased to $97 million.

Accelerated Enrollment in Phase III Studies

Enrollment for the Phase III studies across Lonvo-z and nex-z is faster than expected, with strong interest from both patients and physicians. The company anticipates completing enrollment earlier than planned.

Expansion of Phase III Magnitude Study

Intellia decided to increase enrollment for the Phase III study evaluating nex-z in ATTR cardiomyopathy to 1,200 patients, which will provide a more robust data set without impacting projected cash runway.

Positive Interim Data Presentations

Positive interim data was presented showing long-term follow-up results for Lonvo-z and nex-z, indicating potential to set new standards for HAE and ATTR amyloidosis treatment.

Financial Resilience

Intellia reported solid financials with a cash runway into the first half of 2027, maintaining a strong balance sheet and reducing GAAP operating expenses by approximately 10%.

Intellia Therapeutics (NTLA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NTLA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-1.01 / -	-1.34	―	―	―
Aug 07, 2025	2025 (Q2)	-1.02 / -0.98	-1.52	35.53% (+0.54)	―
May 08, 2025	2025 (Q1)	-1.28 / -1.10	-1.12	1.79% (+0.02)	―
Feb 27, 2025	2024 (Q4)	-1.33 / -1.27	-1.46	13.01% (+0.19)	―
Nov 07, 2024	2024 (Q3)	-1.39 / -1.34	-1.38	2.90% (+0.04)	―
Aug 08, 2024	2024 (Q2)	-1.22 / -1.52	-1.4	-8.57% (-0.12)	―
May 09, 2024	2024 (Q1)	-1.37 / -1.12	-1.17	4.27% (+0.05)	―
Feb 22, 2024	2023 (Q4)	-1.44 / -1.46	-1.4	-4.29% (-0.06)	―
Nov 09, 2023	2023 (Q3)	-1.50 / -1.38	-1.49	7.38% (+0.11)	―
Aug 03, 2023	2023 (Q2)	-1.32 / -1.40	-1.33	-5.26% (-0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NTLA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$11.37	$11.46	+0.79%
May 08, 2025	$7.29	$8.28	+13.58%
Feb 27, 2025	$10.80	$10.86	+0.56%
Nov 07, 2024	$16.06	$16.00	-0.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Intellia Therapeutics (NTLA) report earnings?

Intellia Therapeutics (NTLA) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Intellia Therapeutics (NTLA) earnings time?

Intellia Therapeutics (NTLA) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NTLA EPS forecast?

NTLA EPS forecast for the fiscal quarter 2025 (Q3) is -1.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing